Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Mid-range Performer
383.1000 -8.30 (-2.12%)
NSE Aug 01, 2025 15:31 PM
Volume: 3.1M
 

383.10
-2.12%
Axis Direct
Management indicated that R&D costs will increase in the upcoming quarters which may pose threat to the current margins of the company. We, therefore, recommend a HOLD rating on the stock with a TP of Rs 310/share.
Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.
More from Biocon Ltd.
Recommended